Eidos Therapeutics, a BridgeBio company
13
2
4
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
15.4%
2 terminated/withdrawn out of 13 trials
75.0%
-11.5% vs industry average
54%
7 trials in Phase 3/4
67%
4 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
Role: collaborator
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Role: lead
Cardiac Amyloidosis Discovery Trial
Role: collaborator
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Role: lead
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Role: lead
Open-Label Study of AG10 in Patients with Cardiomyopathy
Role: lead
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Role: collaborator
Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)
Role: lead
Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10
Role: lead
A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects
Role: lead
Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy
Role: lead
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Role: lead
Study of AG10 in Amyloid Cardiomyopathy
Role: lead
All 13 trials loaded